hotspot -WSS

hotspot

author：fashion 2025-09-10 08:44:34 - browse：26933

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Allen Institute goes after foundational questions, CEO Costa says

leisure time

WSS

Latest bird flu infection made farmworker sicker than earlier cases

Merck to acquire Harpoon Therapeutics for $680 million

Boston Scientific acquires urology company Axonics for $3.7 billion

Merck to acquire Harpoon Therapeutics for $680 million

iTeos Therapeutics debuts first data on TIGIT

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

explore

hotspot

focus

Anesthesiologist group: stop taking Ozempic before surgery

Nonprofit, backed by Microsoft, to certify AI tools in health care

Hollywood unions extend contract negotiations for actors

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

As demand for Covid shots wanes, Moderna seeks its next success

JPM pitch from hospitals? Revenue streams outside of patient care

Walensky prepares to leave CDC — and Congress — behind

FDA early review: GLP

Apple is now the first public company to be valued at $3 trillion

Arena BioWorks launches in Cambridge to speed drug discovery

entertainment

iTeos Therapeutics debuts first data on TIGIT

Startling documents reveal new facets of Sacklers' opioid empire

Does Paxlovid work in people vaccinated against Covid

Medicare Advantage coverage denials need scrutiny, senators say

Merck to acquire Harpoon Therapeutics for $680 million

First Opinion Podcast: What happens when kids become caregivers?

leisure time

focus

entertainment

hotspot